Mankind Pharmaceuticals Ltd and Glenmark Pharmaceuticals Ltd today inked a sub-licensing agreement to co-market anti-diabetes drug remogliflozin etabonate in India. Under the agreement, Mankind Pharma will market Remogliflozin under its own trademark while Glenmark will manufacture and supply the drug to the company.

(Live Mint)